

Adrenergic uptake inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/A37499A35AFEN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: A37499A35AFEN

Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "Adrenergic Uptake Inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Adrenergic Uptake Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Adrenergic Uptake Inhibitors Understanding

Adrenergic Uptake Inhibitors: Overview

Adrenergic drugs are a broad class of medications that bind to adrenergic receptors throughout the body. These receptors include: alpha-1, alpha-2, beta-1, beta-2, beta-3. Adrenergic drugs will bind directly to one or more of these receptors to induce various physiologic effects. This activity examines the pharmacology, various therapeutic effects, and adverse events that class members can exert, which covers a wide variety of clinical manifestations.

Function - The adrenergic receptors or adrenoceptors are a class of G protein-coupled receptors that are targets of many catecholamines like norepinephrine (noradrenaline) and epinephrine (adrenaline) produced by the body

Adrenergic Uptake Inhibitors - Adrenergic Uptake Inhibitors are drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.

Adrenergic Uptake Inhibitors Emerging Drugs Chapters

This segment of the Adrenergic Uptake Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Adrenergic Uptake Inhibitors Emerging Drugs

Ampreloxetine: Theravance Biopharma

Ampreloxetine is an investigational, once-daily norepinephrine reuptake inhibitor (NRI) being developed for the treatment of patients with symptomatic neurogenic orthostatic hypotension (nOH). The compound has high affinity for binding to norepinephrine transporters. By blocking the action of these transporters, ampreloxetine causes an increase in extracellular concentrations of norepinephrine. Currently, it is in phase 3 of development stage.

Edivoxetine: Eli Lilly and Company

Edivoxetine (LY-2216684) is an antidepressant produced by US drug major Eli Lilly. The drug acts as a selective norepinephrine reuptake inhibitor and as a treatment for attention-deficit hyperactivity disorder (ADHD). Currently, it is in phase II/III stage of development

Further product details are provided in the report.....

Adrenergic Uptake Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Adrenergic Uptake Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Adrenergic Uptake Inhibitors

There are approx. 15+ key companies which are developing the Adrenergic Uptake Inhibitors. The companies which have their Adrenergic Uptake Inhibitors drug candidates in the most advanced stage, i.e. phase III include, Theravance Biopharma.

Phases

DelveInsight's report covers around 15+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Adrenergic Uptake Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Adrenergic Uptake Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Adrenergic Uptake Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Adrenergic Uptake Inhibitors drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Adrenergic Uptake Inhibitors R&D. The therapies under development are focused on novel approaches for Adrenergic Uptake Inhibitors.

Adrenergic Uptake Inhibitors Report Insights

Adrenergic Uptake Inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Adrenergic Uptake Inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Adrenergic Uptake Inhibitors drugs?

How many Adrenergic Uptake Inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Adrenergic Uptake Inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Adrenergic Uptake Inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Adrenergic Uptake Inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Theravance Biopharma

Eli Lilly and Company

NLS Pharmaceuticals Ltd

DOV Pharmaceutical

Tonix Pharmaceuticals Holding Corp

Taiho Pharmaceutical

Luye Pharma

AbbVie

Otsuka Pharmaceutical

Axsome Therapeutics

Sumitomo Dainippon Pharma

Torrent Pharmaceuticals

NeuroSearch

Otsuka America Pharmaceutical

YooYoung Pharmaceuticals

MultiCell Technologies

Qrono

Apnimed

Key Products

Amprexetine

Edivoxetine

Nolazol

Amitifadine

D 473

TAS 303

Toludesvenlafaxine extended release

Levomilnacipran

Centanafadine

Reboxetine

Dasotraline

Tapentadol intranasal

NS 2359

OPC 64005

YYC301

LAX-202

Quetiapine

AD109

Contents

Introduction

Executive Summary

Adrenergic Uptake Inhibitors: Overview

- Structure
- Mechanism of Action

Pipeline Therapeutics

- Comparative Analysis

Therapeutic Assessment

- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type

Adrenergic Uptake Inhibitors – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

- Adrenergic Uptake Inhibitors companies' collaborations, Licensing, Acquisition -Deal Value Trends

Adrenergic Uptake Inhibitors Collaboration Deals

- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

- Comparative Analysis

Amprelosetine: Theravance Biopharma

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II/III)

- Comparative Analysis

Edivoxetine: Eli Lilly and Company

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

- Comparative Analysis

Drug name: Company name

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

- Comparative Analysis

D 473: Tonix Pharmaceuticals Holding Corp

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

- Comparative Analysis

Adrenergic Uptake Inhibitors Key Companies

Adrenergic Uptake Inhibitors Key Products

Adrenergic Uptake Inhibitors- Unmet Needs

Adrenergic Uptake Inhibitors- Market Drivers and Barriers

Adrenergic Uptake Inhibitors- Future Perspectives and Conclusion

Adrenergic Uptake Inhibitors Analyst Views

Adrenergic Uptake Inhibitors Key Companies

Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Adrenergic uptake inhibitors
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Adrenergic uptake inhibitors
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Adrenergic uptake inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/A37499A35AFEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A37499A35AFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970